34results about "Carrier-antigen complex architecture" patented technology

Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.

The invention provides a composition comprising a Plasmodium species multimeric protein capable of forming a nanoparticle and at least one antigen of interest, wherein the multimeric protein comprises a monomer chosen from Plasmodium species pyridoxal 5'-phosphate synthase (PLP), chaperone 60 protein (Cpn60), and caseinolytic protease (Clp). In embodiments, the invention provides the composition wherein the monomers assemble to form a multimeric nanoparticle and / or which comprises an adjuvant. The invention further provides a nucleic acid encoding the multimeric protein and the at least one antigen of interest, E. coli comprising the nucleic acid, and the use of such in a method for producing the inventive multimeric protein and the at least one antigen of interest. Also provided are a method and use of the inventive multimeric protein and the at least one antigen of interest for immunizing a subject against Plasmodium species.

This application relates to modified H5 influenza hemagglutinin polypeptides and messenger ribonucleic acids (mRNAs) encoding the same, as well as compositions and vaccines comprising the same and methods of using the same, such as in the prevention and / or treatment of diseases or conditions caused by influenza A viruses, particularly influenza A virus, subtype H5, such as H5N8 or H5N1.

Provided are immunogenic compositions comprising respiratory syncytial virus (RSV) viral antigens and immunogens, such as recombinant peptides and proteins comprising RSV F protein peptides. The immunogenic compositions comprise secreted fusion proteins comprising soluble RSV viral antigens linked in-frame to a disulfide-linked trimeric fusion protein. The immunogenic compositions are useful, for example, for generating immune responses to treat or prevent RSV infection. The immunogenic compositions can be used in vaccine compositions, for example, as part of prophylactic and / or therapeutic vaccines. Also provided herein are methods for producing recombinant peptides and proteins, prophylactic, therapeutic, and / or diagnostic methods, and related kits.

The present disclosure describes a peptide scaffold for producing vaccines. The peptide scaffold includes a peptide that self-assembles into a hapten carrier (hC) includes amphipathic alpha-helices. The peptide includes heptad repeats following a specific pattern. The hC further includes hapten or an agent conjugated to it, and optionally the hC includes one or more T-cell epitopes at the N- and / or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions including immunogenic compositions including the hapten-hC or agent-hC conjugate.

Provided herein are compositions and methods related to CMV gB proteins in which amino acid substitutions have been made to disrupt the postfusion state and / or stabilize the prefusion state.

The present invention provides immunogenic compositions comprising a secreted fusion protein, wherein the secreted fusion protein comprises a soluble influenza or rabies virus antigen linked by in-frame fusion to a collagen C-terminal portion capable of self-trimerization to form a disulfide-linked trimeric fusion protein. The present invention also provides uses of the immunogenic compositions for generating an immune response against influenza or rabies infection and for use in vaccine compositions. The present invention also provides methods of producing recombinant peptides and proteins, methods of prevention, treatment, and / or diagnosis, and related kits.

Disclosed herein are methods and compositions for enhancing delivery and function of vaccine components, immunotherapy Agents, and improved delivery of nucleic acid nanostructures, nucleic acids, peptides, polypeptides, and other types of cargoes. These methods and compositions utilize design components suitable for rapid and cost-effective manufacturing, and are designed to exclusively use the process of self-assembly to form nanotherapeutics requiring no purification in many instances.

The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory polypeptide that exhibits reduced binding affinity to a cognate co-immunomodulatory polypeptide. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.

The present disclosure relates to a lipid nanoparticle which is a carrier for an antigen. The present disclosure also relates to an immunogenic composition comprising the antigen. The immunogenic composition may be a vaccine composition. The present disclosure further relates to methods and uses of the carrier and immunogenic composition.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and immunostimulatory agent(s) bound to its surface are provided. The nanostructures can be, for example, in the form of a 6-helix bundle, or icosahedron, or a pentagonal bipyramid. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be a TLR agonist, such as a TLR9 agonist. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses, and for targeted induction of TLR activation are also provided.

Provided herein are vaccine compositions for preparing nanocarriers comprising NiVF and NiVG virus proteins. Methods for preparing and using the nanocarriers for eliciting neutralizing antibodies or treating a Nipah virus infection are also described herein.

Provided herein are antigen-presenting vesicles and compositions of antigen-presenting vesicles presenting antigenic peptides as preventative and therapeutic vaccines for cancer and infection through potent and selective activation of antigen-specific T cells.

Provided herein are compositions and methods relating to the CMV gB protein, in which amino acid substitutions are made to disrupt the post-fusion state and / or stabilize the pre-fusion state.

This invention provides a virus-like particle (VLP) that is formed by a protein of a viral origin (such as from a Hepatitis B virus) and derivatized by way of an isopeptide bond formed between two partner peptides (such as a SpyCatcher / SpyTag connection) to present on the VLP surface one or more antigenic epitopes of a target antigen. Also provided are methods of making the VLP, compositions comprising the VLP, as well as applications of the VLP and the compositions for modulating a recipient's immune response to the target antigen, including immunization against the antigen or desensitization to the antigen.

Polycation carrier particles obtained by polymerizing one or more multiacrylate monomers with one or more hydrophilic monomers to form a crosslink. The polycation carrier particles have a net positive charge. The multiacrylate monomer and the hydrophilic monomer(s) are as defined herein.

One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.

One or more ionizable lipids and lipid nanoparticles containing the same are provided. Also provided is a pharmaceutical composition comprising lipid nanoparticles encapsulating an active agent.

Peptide-based vaccines for inducing an immune response, methods for their production and use are provided. [Solution] The present disclosure relates to novel peptide-based vaccines, methods for producing novel peptide-based vaccines, and their use for delivering peptide antigens to subjects to induce immune responses, particularly T cell responses. The inventors have developed novel compositions and methods for producing peptide-based vaccines that overcome at least one of the limitations of current peptide-based vaccine approaches. The novel peptide-based vaccine compositions and methods for production disclosed herein take into account the variability in the physical and chemical properties of peptide antigens and are therefore generalizable to any peptide antigen.

A bacteriophage T4-based, multivalent / multicomponent, needle and adjuvant-free, mucosal vaccine by engineering spike trimers on capsid exterior and nucleocapsid protein in the interior is disclosed herein. Intranasal administration of this T4-COVID vaccine induces higher virus neutralization antibody titers against multiple variants, balanced Th1 / Th2 antibody and cytokine responses, stronger CD4+ and CD8+ T cell immunity, and higher secretory IgA titers in sera and bronchoalveolar lavage with no effect on the gut microbiota, compared to vaccination of mice intramuscularly. The vaccine is stable at ambient temperature, induce apparent sterilizing immunity, and provide complete protection against original SARS-CoV-2 strain and its Delta variant with minimal lung histopathology. This mucosal vaccine is an excellent candidate for boosting immunity of immunized and / or as a second-generation vaccine for the unimmunized population. This needle-free platform could be used to develop effective vaccines against many other respiratory infectious pathogens including Flu and any future emerging epidemic and pandemic pathogens.

Provided is an antibody or an antigen-binding fragment thereof, a T cell antigen receptor, an immune cell expressing the T cell antigen receptor (TCR), and a preparation method therefor and the use thereof. The TCR can specifically recognize corresponding pMHC complexes, activate TCR T cells, and produce high-level cytokines IFNγ, IL2, TNFα, significantly kill target cells and prolong the life of tumor-bearing mice.

A compound A-L-B, wherein A is a nanoparticle (NP)-forming unit, preferably a NP-forming polypeptide or a NP-forming protein, preferably a NP-forming polypeptide or a NP-forming protein having its C-terminus covalently bound to the N-terminus of L via a peptide bond; L is a polypeptide having the following amino acid sequence written in the single letter code z1–G X1 X2 G X3 G X4 X5 G X6 G X7 G–z2, wherein X1 = any amino acid except H, C, and W, X2 = any amino acid except H, C, and W, X3 = any amino acid except H, C, and W, X4 = any amino acid except H, C, and W, X5 = any amino acid except H, C, and W, X6 = any amino acid except H, C, and W, X7 = any amino acid except H, C, and W, z1 represents the N-terminus of the polypeptide, or a group consisting of 1 to 10 amino acids, and z2 represents the C-terminus of the polypeptide, or a modification of the C- terminal carboxyl group of the polypeptide, which modification (i) forms together with the carboxyl group of the C-terminal amino acid of the polypeptide a moiety having the structure -C(O)-O-R1 or -C(O)-NR2R3, wherein R1 is a functional group selected from the group consisting of -(CH2)n-N3, -(CH2)n-C≡CH, -(CH2)n-difluorooctyne (DIFO), and -(CH2)n-dibenzylcyclooctyne (DIBO); and wherein one of R2 and R3 is H and the other one is a functional group selected from the group consisting of -(CH2)n-N3, -(CH2)n-C≡CH, -(CH2)n-difluorooctyne (DIFO), and -(CH2)n-dibenzylcyclooctyne (DIBO); wherein n = 1, 2, 3, 4, or 5; or (ii) is a polypeptidic catcher group which is able to form an isopeptide bond with a polypeptidic tag group in a catcher / tag pair reaction; or (iii) is a Staphylococcus aureus sortase A transpeptidase recognition site consisting of the amino acids LPXTG, being attached to the C-terminus of the polypeptide via a peptide bond; wherein the side chain of each amino acid of the polypeptide L independently of each other may be chemically modified, in particular phosphorylated, amidated, acetylated, glycosylated, PEGylated, HESylated or combinations thereof; and B is a compound having biological activity, preferably a protein, which preferably has its N-terminus covalently bound to the C-terminus of L via a peptide bond; wherein the N-terminus of L is covalently bound to A, preferably via a peptide bond, and wherein the C-terminus of L is covalently bound to B, preferably via a peptide bond.

Sequential immunization strategies to guide the maturation of antibodies against the human immunodeficiency virus (HIV) are described. The sequential immunization strategies utilize an HIV envelope protein (Env) that binds germline (gl) B cells as a first (prime) immunization and an Env with a functional glycosylated N276 as a second (boost) immunization. The sequential immunization strategies successfully elicit neutralizing antibodies against HIV.

The present invention relates to the development of an engineered polypeptide complex, aimed at inducing protective antibody responses against the Monkey pox virus. The polypeptide complex is structured with antigenic domains connected via specific linkers to a nanocage vehicle. When expressed in a suitable bacterial expression system, the complex generates a recombinant soluble protein that, upon administration in vivo, elicits an immune response that provides protection against Mpox virus infection. The invention also covers the method for producing this engineered polypeptide complex, as well as a vaccine formulation comprising the complex along with pharmaceutically acceptable excipients.

A composition of matter including a binding moiety that binds to antibodies to AAV, a cellular receptor-binding moiety that binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a subject or patient, and optionally, a linker moiety connecting the binding moiety that binds to antibodies to AAV and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing antibodies to AAV in a subject or patient.

Technologies for the prevention and / or treatment of Shigella infections.

The present invention discloses immunogenic compositions including recombinant peptides and proteins comprising human immunodeficiency viruses (HIV) antigens and immunogens, e.g., gp 120 protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble HIV viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing an HIV infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and / or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and / or diagnostic methods, and related kits.

Embodiments of various aspects described herein are directed to methods, compositions, kits for detecting a target molecule in a sample. In particular, there is described herein a multivalent approach which provides an efficient method for detection of small molecules and screening of binding molecules (e.g., antibodies). The multivalent approach uses two or more small molecules in a domain that is attached to a substrate through a linking group. The multivalent domain is free to extend, e.g., into a solution, for presentation to a binding compound such as an antibody.

The present invention provides an albumin nanoparticle, comprising: a neoantigen peptide conjugated to an albumin hitchhiking compound to form a conjugated compound; and a plurality of albumins; wherein the conjugated compound is non-covalently bonded to the plurality of albumins via the albumin hitchhiking compound; wherein the plurality of albumins are non-covalently bonded and covalently crosslinked to each other; and wherein the conjugated compound is configured to be released from the albumin nanoparticle when subjected to pH 6 and below.

In some embodiments, the present disclosure relates to immunogenic compositions, such as coronavirus virus antigens and immunogens, e.g., recombinant peptides and proteins comprising coronavirus S protein peptides. In some embodiments, the immunogenic compositions comprise secreted fusion proteins comprising a soluble coronavirus virus antigen linked by in-frame fusion to the C-terminal portion of a collagen capable of self-trimerizing to form a disulfide-linked trimeric fusion protein. In some embodiments, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing coronavirus infection. In some embodiments, the immunogenic compositions provided herein can be used in vaccine compositions, e.g., as part of a prophylactic and / or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and / or diagnostic methods, and related kits.